ProMetic Signs $19M Tech Transfer and Licensing Deal with Brazilian Institute
ProMetic Life Sciences last week announced that it has signed a $19 million technology transfer and licensing agreement with the Instituto de Tecnologia do Parana (Tecpar) of Brazil to locally manufacture a biopharmaceutical product for the Brazilian domestic market and for other South American countries.
ProMetic will manage the development of a proprietary manufacturing process based on technology from the Biotechnology Research Institute, part of the National Research Council of Canada, and ProMetic’s own bioseparation process, which uses Mimetic Ligand technology.
As part of the agreement, ProMetic has granted to Tecpar an exclusive license to use the technology for a selected undisclosed biopharmaceutical product for the South American market.
ProMetic said that a global budget of $19 million has been earmarked for the project over the next two years, with approximately $9 million allocated to ProMetic for license, milestone, and development payments. Another $10 million will be allocated for the modification of Tecpar’s current facility, the acquisition of dedicated equipment, and the validation process. Tecpar will purchase affinity adsorbents from ProMetic and will pay a royalty on net sales.
Genetic Technologies Hires UTEK to Acquire Non-Coding DNA-Analysis Tech
UTEK will help Genetic Technologies identify genetic-analysis technology from US research groups that GT would use in its genetic-testing business in Australia, GT said last week.
Under the agreement, UTEK, a Tampa, Fla.-based specialty finance company focused on technology-transfer deals, will help GT acquire non-coding DNA-analysis technologies from universities or lab research centers.
GT said it will use the technologies in analytical tests that will be offered to customers in the Asia Pacific region.
Financial terms of the deal were not disclosed.
ISC Subsidiary to Research Stem Cell Therapies for Eye Disease with University of California
International Stem Cell said last week that its subsidiary, Lifeline Cell Technology, has entered into a research agreement with the University of California for three studies involving the use of stem cell therapies in eye diseases.
The project is entitled “Characterization of New Human Embryonic Stem Cell Lines and the Differentiation into Retinal Progenitor Cells,” and will be under the direction of Hans Keirstead, a professor at the Reeve-Irvin Research Center at UC-Irvine.
The research project will include three specific components, ISC said. The first two components will study Lifeline’s proprietary stem cell lines and how they compare to traditionally derived human embryonic stem cells.
The third project will involve differentiating Lifeline’s cell lines into retinal cells and testing them in animal models.
Financial details of the research agreement were not disclosed.